Shanghai Yucardi Biopharmaceuticals

Shanghai Yucardi Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the development of transformative CAR-T cell therapies for hematological malignancies and autoimmune disorders. Founded in 2015, the company leverages its proprietary U-CART platform and specialized technologies like silencing-surface CAR-T (ssCAR-T) to address unmet needs in refractory and relapsed cancers, including those with central nervous system involvement. Their lead candidate, U01, is currently in Phase 2 clinical trials for B-cell acute lymphoblastic leukemia. Yucardi's pipeline also includes dual-target CAR-Ts and programs for multiple myeloma and systemic lupus erythematosus. The company operates its own GMP-compliant manufacturing facilities in Shanghai to support its clinical development and future commercialization efforts.